Teachers Retirement System of The State of Kentucky Invests $1.33 Million in Cogent Biosciences, Inc. $COGT

Key Points

• Teachers Retirement System of the State of Kentucky opened a new position in Cogent Biosciences (NASDAQ:COGT), buying 37,445 shares in Q4 valued at approximately $1.33 million.
• Other institutions ramped up exposure — Fairmount Funds now owns about 9.00 million shares (≈$129.3 million) and Vanguard holds roughly 7.76 million shares (≈$111.4 million), indicating strong institutional interest.
• Cogent posted a quarterly earnings miss (‑$0.55 vs. ‑$0.51 expected), trades near the mid‑$30s with a $6.21B market cap, and analysts are mostly bullish with an average price target of $43.45 and highs up to $55.

Teachers Retirement System of The State of Kentucky purchased a new position in shares of Cogent Biosciences, Inc. (NASDAQ:COGT - Free Report) in the 4th quarter, according to the company in its most recent 13F filing with the SEC. The firm purchased 37,445 shares of the technology company's stock, valued at approximately $1,330,000.

Several other large investors also recently modified their holdings of COGT. Voya Investment Management LLC grew its stake in Cogent Biosciences by 110.0% in the 3rd quarter. Voya Investment Management LLC now owns 61,623 shares of the technology company's stock valued at $885,000 after buying an additional 32,279 shares in the last quarter. Fairmount Funds Management LLC grew its stake in Cogent Biosciences by 44.6% in the 3rd quarter. Fairmount Funds Management LLC now owns 9,003,418 shares of the technology company's stock valued at $129,289,000 after buying an additional 2,777,777 shares in the last quarter. Federated Hermes Inc. grew its stake in Cogent Biosciences by 4,661,150.0% in the 3rd quarter. Federated Hermes Inc. now owns 93,225 shares of the technology company's stock valued at $1,339,000 after buying an additional 93,223 shares in the last quarter. Vanguard Group Inc. grew its stake in Cogent Biosciences by 18.9% in the 3rd quarter. Vanguard Group Inc. now owns 7,757,662 shares of the technology company's stock valued at $111,400,000 after buying an additional 1,234,711 shares in the last quarter. Finally, Campbell & CO Investment Adviser LLC purchased a new position in Cogent Biosciences in the 3rd quarter valued at approximately $885,000.

Cogent Biosciences Stock Down 0.7%

Shares of NASDAQ:COGT opened at $36.34 on Wednesday. The firm has a fifty day moving average price of $36.57 and a two-hundred day moving average price of $34.12. The company has a debt-to-equity ratio of 0.41, a current ratio of 14.23 and a quick ratio of 14.23. Cogent Biosciences, Inc. has a one year low of $4.55 and a one year high of $43.73. The company has a market cap of $6.21 billion, a price-to-earnings ratio of -16.82 and a beta of 0.47.

Cogent Biosciences (NASDAQ:COGT - Get Free Report) last announced its quarterly earnings results on Tuesday, February 17th. The technology company reported ($0.55) EPS for the quarter, missing the consensus estimate of ($0.51) by ($0.04). Analysts anticipate that Cogent Biosciences, Inc. will post -2.14 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

A number of research analysts recently weighed in on the stock. Jefferies Financial Group assumed coverage on shares of Cogent Biosciences in a research note on Monday, March 16th. They issued a "buy" rating and a $55.00 price objective for the company. UBS Group raised shares of Cogent Biosciences to a "strong-buy" rating in a report on Wednesday, January 7th. Piper Sandler raised their price target on shares of Cogent Biosciences from $39.00 to $52.00 and gave the company an "overweight" rating in a report on Wednesday, February 18th. Robert W. Baird set a $35.00 price target on shares of Cogent Biosciences in a report on Thursday, February 19th. Finally, HC Wainwright raised their price target on shares of Cogent Biosciences to $52.00 and gave the company a "buy" rating in a report on Tuesday, January 6th. Two investment analysts have rated the stock with a Strong Buy rating, nine have issued a Buy rating, two have assigned a Hold rating and one has assigned a Sell rating to the company's stock. According to data from MarketBeat, the company has an average rating of "Moderate Buy" and an average price target of $43.45.

About Cogent Biosciences

Cogent Biosciences is a clinical-stage biopharmaceutical company focused on the discovery and development of small-molecule therapies that modulate the tumor microenvironment. The company’s research centers on targeting colony-stimulating factor 1 receptor (CSF1R), a key regulator of tumor-associated macrophages that can promote tumor growth and immune evasion. By selectively inhibiting CSF1R, Cogent Biosciences aims to restore immune surveillance and enhance the efficacy of existing cancer treatments.

The company’s lead asset is an orally bioavailable CSF1R inhibitor that has advanced into early-stage clinical trials for various solid tumors.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.